Next Article in Journal
An Improved Power Law for Nonlinear Least-Squares Fitting?
Previous Article in Journal
Adjustable Robust Singular Value Decomposition: Design, Analysis and Application to Finance
Article Menu

Export Article

Open AccessArticle
Data 2017, 2(3), 30; doi:10.3390/data2030030

Estimating Cost Savings from Early Cancer Diagnosis

1,2,†,* , 3,‡
Quantigic® Solutions LLC, 1127 High Ridge Road, #135, Stamford, CT 06905, USA
Free University of Tbilisi, Business School & School of Physics, 240, David Agmashenebeli Alley, 0159 Tbilisi, Georgia
Two29 Consulting LLC, 46 Sewell Avenue, Piscataway, NJ 08854, USA
Centre for Computational Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore
Zura Kakushadze, Ph.D., is the President and a Co-Founder of Quantigic® Solutions LLC and a Full Professor in the Business School and the School of Physics at Free University of Tbilisi.
Rakesh Raghubanshi, B.A. is an independent consultant with over 20 years of experience in the field of pharmaceutical research and development and has consulted for such companies as Cordis Corporation (then a Johnson & Johnson company, now a Cardinal Health company), Bayer AG and Ferring Pharmaceuticals.
Willie Yu, Ph.D., is a Research Fellow at Duke-NUS Medical School.
Author to whom correspondence should be addressed.
Received: 18 July 2017 / Revised: 23 August 2017 / Accepted: 30 August 2017 / Published: 4 September 2017
View Full-Text   |   Download PDF [251 KB, uploaded 5 September 2017]


We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence rates. A rough estimate for the U.S. national annual treatment cost-savings from early cancer diagnosis is in 11 digits. Using this estimate and cost-neutrality, we also estimate a rough upper bound on the cost of a routine early cancer screening test. View Full-Text
Keywords: cancer; costs; incidence; stage; early diagnosis; treatment; data cancer; costs; incidence; stage; early diagnosis; treatment; data
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kakushadze, Z.; Raghubanshi, R.; Yu, W. Estimating Cost Savings from Early Cancer Diagnosis. Data 2017, 2, 30.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics



[Return to top]
Data EISSN 2306-5729 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top